Skip to main content

Inozyme Pharma, Inc.

INZYDelisted Jul 1, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001693011

Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Inozyme Pharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Inozyme Pharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Inozyme Pharma, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hopfner Robert LorneDirector0IndirectJul 3, 20250
Bolte AxelDirector0Jul 3, 20250
Treco Douglas ACEO & Chairman0Jul 3, 20250
Sullivan Lynne MarieDirector–Jul 3, 20250
Subramanian SanjaySVP, CFO & Head of BD0Jul 3, 20250
Winton MatthewCOO0Jul 3, 20250
Harris ErikDirector–Oct 7, 20240
Diaz Reinaldo MDirector–Jun 20, 20240
Mathers Edward TDirector–Jun 20, 20240
Edwards MartinDirector–Jun 20, 20240
Bhagat Sarah MDirector–Jun 20, 20240
Pivotal bioVenture Partners Fund I, L.P.Director1,571,741IndirectAug 3, 20230
Pivotal bioVenture Partners Fund I U.G.P. LtdDirector1,571,741IndirectAug 3, 20230
Pivotal bioVenture Partners Fund I G.P., L.P.Director1,571,741IndirectAug 3, 20230
Bjarke Henric BjornSVP, COO105,441Dec 19, 20220
Enright Patrick G10% Owner4,174,379IndirectApr 21, 20220
Tammenoms Bakker Juliet10% Owner4,174,379IndirectApr 21, 20220
Longitude Venture Partners III, L.P.10% Owner4,174,379IndirectApr 21, 20220
Longitude Capital Partners III, LLC10% Owner4,174,379IndirectApr 21, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 3, 2025 (view filing)Apr 21 dayTreco Douglas ACEO & ChairmanSSale−8.82K$0.89−$7.85K−17.7%41.0K after
Apr 3, 2024 (view filing)Apr 21 dayTreco Douglas ACEOSSale−7.52K$6.94−$52.2K−26.7%20.7K after
Aug 3, 2023 (view filing)8:13 PM ETAug 12 daysPivotal bioVenture Partners Fund I, L.P. and 2 othersDirectorPPurchase+833.3K$4.80+$4.00M+112.9%1.57M after2 lotsDuplicate filing
Aug 3, 2023 (view filing)Aug 12 daysHopfner Robert LorneDirectorPPurchase+833.3K$4.80+$4.00M+112.9%1.57M after2 lots
May 15, 2023 (view filing)May 11-124 daysHopfner Robert LorneDirectorPPurchase+447.9K$6.36+$2.85M+13.9%3.66M after2 lots
Mar 30, 2023 (view filing)Mar 291 dayHopfner Robert LorneDirectorPPurchase+344.6K$4.54+$1.56M+12.0%3.21M after
Mar 29, 2023 (view filing)Mar 27-282 daysHopfner Robert LorneDirectorPPurchase+207.8K$4.05+$841.1K+7.8%2.87M after2 lots
Dec 19, 2022 (view filing)Dec 154 daysBjarke Henric BjornSVP, COOPPurchase+21.5K$1.39+$29.9K+25.6%105.4K after
Apr 21, 2022 (view filing)6:04 PM ETApr 192 daysEnright Patrick G and 3 others10% OwnerPPurchase+1.35M$3.69+$5.00M+48.1%4.17M after
Apr 20, 2022 (view filing)6:22 PM ETApr 191 dayPivotal bioVenture Partners Fund I, L.P. and 2 othersDirectorPPurchase+1.07M$3.69+$3.95M+67.2%2.66M afterDuplicate filing
Apr 20, 2022 (view filing)Apr 191 dayHopfner Robert LorneDirectorPPurchase+1.07M$3.69+$3.95M+67.2%2.66M after
Apr 20, 2022 (view filing)Apr 191 dayBjarke Henric BjornSVP, COOPPurchase+27.1K$3.69+$100.0K+50.6%80.6K after
Apr 20, 2022 (view filing)Apr 191 dayBolte AxelChief Executive OfficerPPurchase+67.8K$3.69+$250.0K+35.5%258.6K after
Apr 20, 2022 (view filing)Apr 191 daySubramanian SanjaySVP, CFOPPurchase+27.1K$3.69+$100.0KNew position27.1K after